Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipophilic statins linked to lower mortality in ovarian cancer

Publish date:: July 6, 2020

Key clinical point: Lipophilic statin use may reduce mortality risk in patients with ovarian cancer.

Major finding: Lipophilic statin use was associated with a 43% reduction in mortality (weighted hazard ratio, 0.57).

Study details: An observational study of 10,062 patients with epithelial ovarian cancer, 2,621 of whom were exposed to statins.

Disclosures: The Department of Defense and the Breast Cancer Research Foundation funded the study. The researchers disclosed no conflicts of interest.

Citation:

Visvanathan K et al. AACR 2020, Abstract 5782.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,